Sanofi: Settlement with Lilly about SoloStar litigation

Sanofi and Lilly have settled their patent dispute in the US. As a consequence, biosimilar Lantus SoloStar will not hit the US market before mid December next year. 2016 is therefore likely to be clean of major headwinds and Sanofi is given 6 extra months to transform its Diabetes franchise.

For more information, please contact marketing@bryangarnier.com